 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Nevirapine Prolonged Release Once-Daily Formulation Available in the UKJanuary/February 2012 Following the approval in Europe last year of a prolonged release (PR) formulation of nevirapine (called extended release/XR in the US), this 400 mg once-daily tablet is now available in the UK. The lead in dose of 200 mg once daily (using the original formulation) is still required, with the same caution not to increase to the 400 mg daily dose if the patient shows rash at the end of these 14 days. The daily price of nevirapine PR has been price matched to the price of the 200 mg formulation. Reference
Links to external websites are current at time of posting but not maintained.  This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|
Email
Comments
Print-Friendly
Glossary
PDF
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
